By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at


August 7, 2007


Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su

CEO: David Schenkein

CMO (Medical): Chris Bowden

CSO (Scientific): Scott Biller


Please click here for Agios job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Agios
Symbol: AGIO

Company News
Agios (AGIO) Could Soon Pocket $169 Million From Celgene (CELG) on Selection of New Cancer Candidate 3/13/2017 7:14:17 AM
9 Massachusetts Biotechs Facing Major FDA Decisions This Year 3/3/2017 6:16:42 AM
Agios (AGIO) Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Key 2017 Milestones 2/16/2017 8:09:30 AM
Agios (AGIO) To Webcast Conference Call Of Fourth Quarter And Full Year 2016 Financial Results On February 16, 2017 2/9/2017 8:16:11 AM
Agios (AGIO) Announces Key Upcoming Milestones To Support Evolution To A Commercial Stage Biopharmaceutical Company In 2017 1/9/2017 8:09:40 AM
Agios (AGIO) Appoints Ian Clark To Board Of Directors 1/3/2017 8:01:13 AM
Cambridge Biotech Agios (AGIO) Terminates AG-519 for PK Deficiency, But Continues AG-348 For Same Condition 12/16/2016 6:27:05 AM
Agios (AGIO) Announces New Clinical Data From Dose-Escalation Portion Of Phase I Trial Of Single Agent AG-120 Showing Durable Molecular Responses In Patients With Advanced Hematologic Malignancies 12/6/2016 7:56:55 AM
Agios (AGIO) Announces New Data From AG-348 And AG-519 Demonstrating Potential For First Disease-Modifying Treatment For Patients With PK Deficiency 12/5/2016 8:49:49 AM
Agios (AGIO) Announces Phase I Data From Dose Expansion Cohorts Of AG-120 In Patients With IDH1 Mutant Positive Glioma And Chondrosarcoma 11/21/2016 10:52:56 AM